Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

The ALK in Lung Cancer Trial of brigAtinib in First Line (ALTA‐1L) compared brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK) inhibitor‐naive patients with ALK+ non‐small cell lung cancer (NSCLC). A population pharmacokinetic (PK) model was used to estimate brigatinib exposures for ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Reckamp, Karen L., Camidge, David R., Kleijn, Huub J., Ouerdani, Aziz, Bellanti, Francesco, Maringwa, John, Hanley, Michael J., Wang, Shining, Zhang, Pingkuan, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099121/
https://www.ncbi.nlm.nih.gov/pubmed/35041775
http://dx.doi.org/10.1111/cts.13231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099121/
https://www.ncbi.nlm.nih.gov/pubmed/35041775
http://dx.doi.org/10.1111/cts.13231

Ejemplares similares